News

Public · Published

Oracle prices $20B stock and bond offering amid AI expansion, sets share sale at $116

Oracle priced a combined $20B stock and bond offering: 86.2 million shares at $116 each (an 11.2% discount to its $130.67 close) raising about $9.9B net, plus $10B of senior notes, which are borrowed-money bonds, due 2029 to 2046. Both close November 4.

Published:

Updated:

What happened

Oracle priced a combined $20B stock and bond offering: 86.2 million shares at $116 each (an 11.2% discount to its $130.67 close) raising about $9.9B net, plus $10B of senior notes, which are borrowed-money bonds, due 2029 to 2046. Both close November 4.

Confirmed

Global impact / market context

Oracle is taking in roughly $20B to fund AI infrastructure and repay debt, but selling shares at a discount dilutes existing owners, meaning their stakes shrink. Higher debt raises interest costs, so future profit depends on whether AI spending earns enough to cover these added expenses.

Analyst inference

The stock fell about 9% to $119.2 on November 2 as investors questioned AI spending costs and returns. This fundraising follows the October 28 investor day, where Oracle committed to limit extra capital-market funding for its FY2027 to FY2030 investment cycle to $20B, excluding some items.

Analyst inference

What to watch

  1. Watch whether both offerings close on November 4 as stated, since the $9.9B net stock proceeds and roughly $10B net bond proceeds fund capital spending, which means long-term investments, debt repayment and possible dividends. Confirmed
  2. Track how Oracle actually uses the cash: the stated plan lists general corporate purposes, including capital spending, debt repayment, investments or acquisitions, dividends and share repurchases, so the mix could shift. Proposed
  3. Monitor whether AI cloud capacity spending turns into revenue and profit fast enough to cover new interest costs from 7% to 8.65% bonds and offset share dilution, which means existing owners hold smaller stakes. Analyst inference

Evidence